Last updated on August 2020

Efficacy and Systemic Safety of Netarsudil 0.01% 0.02% 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan


Brief description of study

Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan

Clinical Study Identifier: NCT03844945

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.